Device Trial Radar · NCT05063565
TheraSphere With Durvalumab and Tremelimumab for HCC
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 3, 2023
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- Collaborators
- Biocompatibles UK Ltd
- First posted
- Oct 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
Conditions
- Hepatocellular Carcinoma
Interventions
TheraSphere Y-90 glass microsphere therapyDevice
TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
Durvalumab (Imfinzi) immunotherapyDrug
1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met: * Absence of clinical symptoms or signs indicating clinically significant disease progression * No decline in performance status * Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention * No other treatment discontinuation criteria are met
Tremelimumab immunotherapyDrug
300 mg, single administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Start of Treatment (Day 1) up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (18 months after the last patient is treated)
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
University of California San Diego
San Diego, California
34 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.